Netherlands Pharmaceuticals and Healthcare Report Q2 2008 : Market Research Report

Netherlands Pharmaceuticals and Healthcare Report Q2 2008

Published by: Business Monitor International

Published: May. 16, 2008 - 70 Pages

Executive Summary: Netherlands Pharmaceuticals And Healthcare Industry S; Pharmaceutical Business Environment Ratings; Table: Western European Pharmaceutical Business Environment Ratings; Limits To Potential Returns; Risks To Realisation Of Returns; Market Summary; Regulatory Regime; Intellectual Property Developments; Pricing And Reimbursement; OTC Medicines; Industry Developments; Healthcare Sector; Healthcare Insurance; Table: Key Points - Dutch Health Insurance Act, January 106; Health Profile; Pharmaceuticals Sector; Recent Domestic Companies’ Activities; Recent Foreign Companies’ Activities; Research And Development Sector; Industry Forecast Scenario; Overall Market Forecast; Table: The Netherlands Drug Market Forecast Indicators; Key Growth Factors - Industry; Table: Netherlands Health Expenditure Indicators; Key Growth Factors - Macroeconomic; Table: Netherlands - Macroeconomic Forecasts; Patented Market Forecast; Table: The Netherlands’ Patented Drug Market Forecast Indicators (US$mn unless otherwise stated); Over-The-Counter Market Forecast; Table: The Netherlands OTC Drugs Market Forecast Indicators (US$mn unless otherwise stated); Generics Forecasts; Table: The Netherlands’ Generics And Branded Market Forecast Indicators; Export/Import Forecasts; Table: The Netherlands’ Pharmaceutical Trade Forecast Indicators (US$mn); Key Risks To BMI’s Forecast Scenario; Competitive Landscape; Company Profiles; Leading Multinational Manufacturers; Merck & Co; Pfizer; GlaxoSmithKline (GSK); Sanofi-Aventis; Novartis; Indigenous Manufacturers; Akzo Nobel; DSM; Qiagen; Pharming Group; Crucell; BMI Forecast Modelling; How We Generate Our Industry Forecasts; Pharmaceutical Industry; Pharmaceutical Business Environment Ratings Methodology; Ratings Overview; Table: Pharmaceutical Business Environment Indicators; Weighting; Table: Weighting Of Components; Sources

Abstract

Growth will be far from impressive for the drug market in the Netherlands over the forecast period, although, in many ways this reflects the general sluggishness seen in mature markets. BMI expects the market to reach a value of US$7.06bn in 2012, representing a compound annual growth rate (CAGR) of2.08%. Growth will be strongest in the generics market but should also be reasonable for consumer health products as these medicines benefit from government liberalisation policies.

The generics sector, however, will be negatively impacted by the new transition agreement regarding pharmaceutical prices that has come into effect. In January 2008, the price of generic medicines was reduced by 10%. BMI has factored this decrease into our forecasts and believes that the generics market will reach a value of US$1.28bn by 2012. In addition, medicines whose patents expire in 2008 will see price cuts of 50%. The Dutch Pharmacy Association, KNMP, claims that the plans are designed to keep the cost of medicines down. Also, they are designed to help transform the pharmaceutical market from being supply-based to being demand-based.

In terms of company activity, the sector has been quiet after last year saw US drug maker Schering-Plough acquire Organon, the pharmaceuticals division of Dutch industrial conglomerate Akzo Nobel for EUR11bn (US$14.5bn). However, in February 2008, a Dutch court ruled against US drug maker Pfizer in a court case regarding the patent on atorvastatin, the key ingredient in cholesterol reducing drug Lipitor is invalid. This is a severe blow for Pfizer, as it could open the door for generic competition for its best selling drug.

Meanwhile, recent attacks by animal extremists in the Netherlands have forced a local company to pullout of a life sciences project. BMI believes that the latest problems in the Netherlands, if sustained, will have a negative impact on the country's Business Environment Rating. The Netherlands has a respected regulatory system, with an average score of eight across our three main indicators, but we will down grade the scores if intimidation of the research sector is permitted to continue.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Netherlands Pharmaceuticals and Healthcare Report Q2 2008

Table of Contents

Abstract